<DOC>
	<DOCNO>NCT01381406</DOCNO>
	<brief_summary>This retrospective cohort design use administrative claim data Jan 1 , 2003 Sep 30 , 2007 , represent year available data , use study . Managed care enrollees least one pharmacy claim tiotropium ( TIO ) study period identify target population . An index TIO prescription define first chronologically occur pharmacy claim TIO period Jan 1 , 2004 Aug 31 , 2006 , call enrollment period . The date index TIO prescription term index Rx date , 1-year period index Rx date term pre-index period . The period index date term post-index date , divide 30-day combination assessment period 1-year follow-up period . COPD clinical economic outcome measure variable length follow period . The combination assessment period , define 30-day period follow index Rx date , use categorize patient 2 cohort : TIO alone TIO + FSC ( fluticasone propionate/salmeterol xinofoate combination ) depend whether use FSC combination TIO period . Combination therapy TIO + FSC define FSC claim date TIO claim TIO FSC pharmacy claim overlap day supply occur within 30 day index Rx date . Enrollees add FSC first time 30-day combination assessment period exclude sample , thus ensure TIO-alone cohort use FSC . No outcomes assess 30-day combination assessment period . The 1-year period end 30-day combination assessment period term follow-up period use ass study outcome . Enrollees require continuously eligible health plan pre-index post-index period total 25 month . An intent-to-treat approach use analysis . Thus , patient identify drug therapy cohort consider use therapy entire follow-up period , regardless therapy discontinuation . Specifically study hypothesis primary outcome test : Ho : There difference risk COPD-related exacerbation TIO+FSC TIO cohorts Ha : There difference risk COPD-related exacerbation TIO+FSC TIO cohorts Hypothesis key secondary outcome COPD-related cost test : Ho : There difference COPD-related cost TIO+FSC TIO cohorts Ha : There difference COPD-related cost TIO+FSC TIO cohort</brief_summary>
	<brief_title>Impact Initiating Tiotropium Alone Versus Initiating Tiotropium Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination ( FSC ) Chronic Obstructive Pulmonary Disease-related Outcomes Patients With Pre-existing Exacerbations</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Continuous health plan eligibility pre postindex period age ≥40 year index date Presence least 1 claim ICD9CM code COPD diagnosis field ( 490.xx , 491.xx , 492.xx , 496.xx ) pre postindex period ≥1 exacerbation preindex period ( define COPDrelated Emergency Room visit hospitalization ) ≥1 prescription claim ipratropium ipratropium/albuterol combination preindex period index event least one pharmacy claim TIO ( tiotropium ) combination preindex period study period ( January 1 , 2003 April 30 , 2008 ) ≥2 prescription TIO ( include index prescription ) postindex period presence comorbid condition ( respiratory cancer , cystic fibrosis , fibrosis due tuberculosis [ TB ] , bronchiectasis , pneumonociosis , pulmonary fibrosis , pulmonary TB , sarcoidosis ) pre postindex period use FSC preindex period exacerbation ( emergency room visit hospitalization ) within 30 day index date</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>